SGEN and LVTX Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors.
LAVA to Receive Upfront Payment of $50M$LAVA Therapeutics(LVTX)$
| 发布于: | Android | 转发：0 | 回复：0 | 喜欢：0 |
SGEN and LVTX Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors.
LAVA to Receive Upfront Payment of $50M$LAVA Therapeutics(LVTX)$